Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study

During the 2023 Danish COVID-19 vaccination campaign, an updated monovalent mRNA vaccine targeting the SARS-CoV-2 omicron XBB.1.5 subvariant was administered. However, the rapid spread of a genetically divergent omicron BA.2.86 subvariant, JN.1, since September, 2023, poses potential challenges due...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet infectious diseases 2024-09, Vol.24 (9), p.964-973
Hauptverfasser:	Moustsen-Helms, Ida Rask, Bager, Peter, Larsen, Tine Graakjær, Møller, Frederik Trier, Vestergaard, Lasse Skafte, Rasmussen, Morten, Hansen, Christian Holm, Christiansen, Lasse Engbo, Gubbels, Sophie, Trebbien, Ramona, Westergaard, Casper, Escobar-Herrera, Leandro Andrés, Gunalan, Vithiagaran, Ring, Aleksander, Bennedbæk, Marc, Steenhard, Nina, Mørk Hartmann, Esben, Nielsen, Lene, Terp Andersen, Dorte, Thomsen, Marianne Kragh, Marmolin, Ea Sofie, Vognbjerg Sydenham, Thomas, Hoegh, Silje Vermedal, Pinholt, Mette, Møller, Josefine Tange, Vasehus Madsen, Tina, Fuglsang-Damgaard, David, Jokelainen, Pikka, Krause, Tyra Grove, Ullum, Henrik, Søborg, Bolette, Valentiner-Branth, Palle
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Comorbidity COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 - virology COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Denmark - epidemiology Disease Female Health risks Health surveillance Hospitalization Humans Infections Intensive care Male mRNA Observational studies Quality control Registration SARS-CoV-2 - genetics SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Severity of Illness Index Signs and symptoms Vaccination Vaccines Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!